M. Hannula

A prolyl oligopeptidase inhibitor, KYP‐2047, reduces α‐synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease

V. Baekelandt, R. Van Elzen, M. Gérard, 2012, British journal of pharmacology.